John Strickler, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept of Medicine, Box 2823, Durham, NC 27710
Phone (919) 668-6608
Email address john.strickler@duke.edu
In Their Words

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2008 - 2011
  • Residency, Medicine, University of Washington, 2005 - 2008
  • M.D., University of Chicago, 2005

Publications

Bekaii-Saab, Tanios, Richard Kim, Tae Won Kim, Juan Manuel O’Connor, John H. Strickler, David Malka, Andrea Sartore-Bianchi, et al. “Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.” Clinical Colorectal Cancer 18, no. 1 (March 1, 2019): E117–29. https://doi.org/10.1016/j.dcc.2018.11.002.

Full Text

Bekaii-Saab, Tanios, Richard Kim, Tae Won Kim, Juan Manuel O’Connor, John H. Strickler, David Malka, Andrea Sartore-Bianchi, et al. “Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice..” Clin Colorectal Cancer 18, no. 1 (March 2019): e117–29. https://doi.org/10.1016/j.clcc.2018.11.002.

PMID
30598357
Full Text

Parseghian, C. M., J. M. Loree, V. K. Morris, X. Liu, K. K. Clifton, S. Napolitano, J. T. Henry, et al. “Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge..” Ann Oncol 30, no. 2 (February 1, 2019): 243–49. https://doi.org/10.1093/annonc/mdy509.

PMID
30462160
Full Text

Turner, Megan C., Jeffrey E. Keenan, Christel N. Rushing, Brian C. Gulack, Daniel P. Nussbaum, Ehsan Benrashid, Terry Hyslop, John H. Strickler, Christopher R. Mantyh, and John Migaly. “Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response..” In J Gastrointest Surg, 2019. https://doi.org/10.1007/s11605-018-04079-8.

PMID
30635829
Full Text

Strickler, John H., Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, et al. “First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors..” J Clin Oncol 36, no. 33 (November 20, 2018): 3298–3306. https://doi.org/10.1200/JCO.2018.78.7697.

PMID
30285518
Full Text

Graham, Christopher N., Alexandra Christodoulopoulou, Hediyyih N. Knox, Lorenzo Sabatelli, Guy Hechmati, Tamer Garawin, and John H. Strickler. “A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US..” J Med Econ 21, no. 11 (November 2018): 1075–83. https://doi.org/10.1080/13696998.2018.1510409.

PMID
30091652
Full Text

Klempner, S. J., J. Bendell, V Meucci Villaflor, L. Tenner, S. Stein, C. A. Sirard, W. Newman, M. Kagey, K. Schlienger, and J. Strickler. “Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies.” In Annals of Oncology, 29:222–222. OXFORD UNIV PRESS, 2018.

Scholars@Duke

Camidge, R., R. S. Heist, J. Goldman, E. Angevin, J. Strickler, D. Morgensztern, M. Barve, et al. “An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T plus E) in non-small cell lung cancer (NSCLC).” In Annals of Oncology, Vol. 29. OXFORD UNIV PRESS, 2018.

Scholars@Duke

Wainberg, Z., J. Strickler, M. Gordon, M. Barve, L. Wang, H. Yue, M. Motwani, S. Kasichayanula, L. Naumovski, and E. Hamilton. “Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC).” In Annals of Oncology, 29:66–66. OXFORD UNIV PRESS, 2018.

Scholars@Duke

Wainberg, Z., L. Wang, H. Yue, M. Motwani, S. Kasichayanula, M. Blaney, L. Naumovski, and J. Strickler. “ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress.” In Annals of Oncology, Vol. 29. OXFORD UNIV PRESS, 2018.

Scholars@Duke

Pages